This Article Full Text Full Text (PDF) All Versions of this Article: j.jacc.2008.03.006v1 51/17/1704    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (21) Citing Articles via Google Scholar Google Scholar Articles by Kusnetzky, L. L. Articles by Main, M. L. Search for Related Content PubMed Articles by Kusnetzky, L. L. Articles by Main, M. L.

EXPEDITED PUBLICATION: SHORT ORIGINAL RESEARCH PAPER

Acute Mortality in Hospitalized Patients Undergoing Echocardiography With and Without an Ultrasound Contrast Agent

Results in 18,671 Consecutive Studies

Saint Luke's Mid America Heart Institute, Kansas City, Missouri.

Manuscript received January 16, 2008; revised manuscript received February 26, 2008, accepted March 5, 2008.

^_* Reprint requests and correspondence: Dr. Michael L. Main, Saint Luke's Mid America Heart Institute, 4330 Wornall Road, Suite 2000, Kansas City, Missouri 64111. (Email: mmain{at}cc-pc.com).

Objectives: We sought to define acute mortality in hospitalized patients undergoing clinically indicated echocardiography with and without use of an ultrasound contrast agent.

Background: The U.S. Food and Drug Administration recently issued a boxed warning and new contraindications for the perflutren-containing ultrasound contrast agents following post-marketing reports of 4 patient deaths that were temporally related to Definity (Bristol-Myers Squibb Medical Imaging, Billerica, Massachusetts) administration. To appreciate the incremental risk of any medical procedure, the ambient risk of untoward outcome in the population in question must first be defined. There are no published data on short-term major adverse cardiac events in hospitalized patients undergoing echocardiography, either with or without administration of an ultrasound contrast agent.

Methods: A retrospective analysis of hospitalized patients undergoing clinically indicated echocardiography between January 2005 and October 2007, within Saint Luke's Health System, Kansas City, Missouri, was performed. Studies were separated into 2 groups, those performed without contrast enhancement (n = 12,475) and those performed with Definity (n = 6,196). Vital status within 24 h of the echocardiographic study was available for all patients using a combination of the Social Security Death Master File and Saint Luke's Health System medical records. Incidence of death within 24 h was compared by chi-square test between Definity and unenhanced procedures.

Results: Of the 18,671 patient events, 72 patients died within 24 h. Of those that underwent unenhanced echocardiography, 46 died within 24 h (0.37%). Of patients receiving Definity during the echocardiogram, 26 died within 24 h (0.42%). There was no statistical difference between these 2 groups (p = 0.60). No patient died within 1 h of the echocardiographic study. In a random sampling from the unenhanced (n = 201) and Definity groups (n = 202), patients who underwent Definity-enhanced echocardiography exhibited higher clinical acuity, and more significant comorbidities.

Conclusions: Approximately 0.4% of hospitalized patients die within 24 h of echocardiography. There is no increased mortality risk associated with Definity-enhanced examinations, despite evidence for higher clinical acuity and more comorbid conditions in patients undergoing contrast studies.

Abbreviations and Acronyms   ACS = acute coronary syndromes   HF = heart failure   LV = left ventricular

This article has been cited by other articles:

				S. T. Laing and D. D. McPherson Cardiovascular therapeutic uses of targeted ultrasound contrast agents Cardiovasc Res, July 6, 2009; (2009) cvp192v1. [Abstract] [Full Text] [PDF]

				S. Achenbach, V. Dilsizian, C. M. Kramer, and W. A. Zoghbi The Year in Coronary Artery Disease J. Am. Coll. Cardiol. Img., June 1, 2009; 2(6): 774 - 786. [Abstract] [Full Text] [PDF]

				A. E. Weyman The year in echocardiography. J. Am. Coll. Cardiol., April 28, 2009; 53(17): 1558 - 1567. [Full Text] [PDF]

				F. M. Asch and N. J. Weissman Overview of the 2008 Food and Drug Administration Advisory Committee on Safety Considerations in the Development of Ultrasound Contrast Agents Circulation, April 14, 2009; 119(14): 1956 - 1961. [Full Text] [PDF]

				M. Kurt, K. A. Shaikh, L. Peterson, K. M. Kurrelmeyer, G. Shah, S. F. Nagueh, R. Fromm, M. A. Quinones, and W. A. Zoghbi Impact of Contrast Echocardiography on Evaluation of Ventricular Function and Clinical Management in a Large Prospective Cohort J. Am. Coll. Cardiol., March 3, 2009; 53(9): 802 - 810. [Abstract] [Full Text] [PDF]

				R. Senior, H. Becher, M. Monaghan, L. Agati, J. Zamorano, J. L. Vanoverschelde, and P. Nihoyannopoulos Contrast echocardiography: evidence-based recommendations by European Association of Echocardiography Eur J Echocardiogr, March 1, 2009; 10(2): 194 - 212. [Abstract] [Full Text] [PDF]

				A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al. Highlights of the Year in JACC 2008. J. Am. Coll. Cardiol., January 27, 2009; 53(4): 373 - 398. [Full Text] [PDF]

				M. S. Dolan, S. S. Gala, S. Dodla, S. S. Abdelmoneim, F. Xie, D. Cloutier, M. Bierig, S. L. Mulvagh, T. R. Porter, and A. J. Labovitz Safety and efficacy of commercially available ultrasound contrast agents for rest and stress echocardiography a multicenter experience. J. Am. Coll. Cardiol., January 6, 2009; 53(1): 32 - 38. [Abstract] [Full Text] [PDF]

				T. H Marwick How dangerous is echocardiographic contrast? Heart, December 1, 2008; 94(12): 1522 - 1523. [Full Text] [PDF]

				H. Becher Contrast agents for echocardiographic studies within 24 h after myocardial infarction Eur J Echocardiogr, November 1, 2008; 9(6): 719 - 720. [Full Text] [PDF]